Benzinga | Dec 1, 2020 08:06AM EST

Cidara Therapeutics To Present Preclinical data For Flu Antiviral Conjugates At European Scientific Working Group on Influenza Conference Dec. 7-8

Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced a keynote lecture, an oral presentation and two posters at the 7th European Scientific Working Group on Influenza (ESWI) Influenza Conference, which takes place virtually Dec. 6-9, 2020.

The Keynote Lecture highlights Cidara's Cloudbreak antiviral platform, specifically its program for universal protection from influenza. Details of the Keynote Lecture are as follows:

Keynote Lecture Programme:Title: Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak(R) Influenza Antiviral Conjugates (AVCs)Speakers: Opening Remarks: Michael Ison, M.D., M.S., professor, Northwestern University Feinberg School of Medicine Keynote Lecture: Les Tari, Ph.D., senior vice president, research, Cidara TherapeuticsDate and Monday, Dec. 7, 2020 at 6:00 p.m. CETTime:

The oral and poster presentations highlight preclinical data from the antiviral conjugate (AVC) candidate, CD377 for prevention and treatment of influenza. Details of the presentations are as follows:

Oral Presentation: Characterization of In Vitro Activity and In Vivo Efficacy ofTitle: CD377, a Novel Anti-Viral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine StrainsPresenter: Jeffrey B. Locke, Ph.D., director, microbiology, Cidara TherapeuticsDate and Dec. 8, 2020 at 2:00 p.m. CETTime:Session: Antiviral and immune therapy for influenza, RSV disease and COVID-19 Poster Presentations:Title: In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI)Presenter: James Levin, Ph.D., senior director of preclinical development, Cidara TherapeuticsFormat: On-demand CD377, a Novel Antiviral Fc-Conjugate, is Equipotent by DifferentTitle: Dosing Routes and Active Against Oseltamivir-Resistant Isolates Of Influenza A (H1N1) in Lethal Mouse Infection ModelsPresenter: James Levin, Ph.D., senior director of preclinical development, Cidara TherapeuticsFormat: On-demand

The Keynote Lecture and copies of the abstracts will be made available on the Publications section of the Cidara website.